新诊断的费城染色体阳性急性淋巴细胞白血病患者中伊马替尼 GRAAPH-2003 研究的长期随访：GRAALL 研究。
Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study.
机构信息
Department of Hematology, Service des Maladies du sang, INSERM U892, PRES LUNAM, University Hospital, Angers, France.
出版信息
Biol Blood Marrow Transplant. 2013 Jan;19(1):150-5. doi: 10.1016/j.bbmt.2012.08.021. Epub 2012 Sep 6.
We report here the results of the GRAAPH-2003 trial with long-term follow-up in 45 patients with de novo Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Imatinib-based strategy improved the 4-year overall survival (OS) up to 52% versus 20% in the pre-imatinib LALA-94 trial (P = .0001). Despite the selection in patients who actually underwent transplantation, these results suggest that allogeneic or autologous stem cell transplants (SCTs) still have a place in overcoming the poor prognosis of Ph+ ALL in the era of imatinib therapy. OS was 50% after allogeneic SCT (24 patients), 33% in patients without a transplantation (9 patients), and 80% after autologous SCT (10 patients without allogeneic donor or >55 years, including 7 patients in complete molecular response).
我们在此报告 GRAAPH-2003 试验的结果，该试验对 45 例初诊费城染色体阳性（Ph+）急性淋巴细胞白血病（ALL）患者进行了长期随访。基于伊马替尼的治疗策略将 4 年总生存率（OS）提高至 52%，而在伊马替尼前 LALA-94 试验中为 20%（P =.0001）。尽管在实际接受移植的患者中进行了选择，但这些结果表明，同种异体或自体干细胞移植（SCT）在伊马替尼治疗时代仍然有一席之地，可以克服 Ph+ ALL 的不良预后。异体 SCT 后 OS 为 50%（24 例），无移植患者为 33%（9 例），自体 SCT 后为 80%（10 例无同种异体供体或>55 岁，包括 7 例完全分子反应）。
Zotero 插件